Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence
Executive Summary
In a recent presentation on evidence-based reimbursement and personalized medicine, a Novartis executive highlights Medicare Part B contractor Palmetto GBA’s molecular diagnostic reimbursement initiative as one to watch.